ntcp
determin
viral
infect
specif
entri
level
hbv
infect
human
chimpanze
northern
treeshrew
tupaia
belangeri
infect
nonhuman
primat
mous
rat
human
sodium
taurochol
cotransport
polypeptid
hntcp
bona
fide
receptor
hbv
hdv
hntcp
express
hepatoma
cell
line
import
tool
studi
hbv
hdv
replic
wenhui
li
stephan
urban
almost
three
decad
follow
discoveri
human
hepat
b
viru
hbv
earli
event
viru
infect
attach
hepatocyt
specif
bind
receptor
hepatocyt
remain
enigmat
gradual
improv
tissu
cultur
system
hbv
enabl
identif
viral
determin
viral
infect
facilit
discoveri
human
sodium
taurochol
cotransport
polypeptid
hntcp
liver
specif
receptor
hbv
satellit
human
hepat
delta
viru
hdv
find
current
lead
basic
clinic
research
activ
new
direct
stabl
hntcpexpress
cell
line
becom
valuabl
platform
studi
full
hbv
replic
cycl
nativ
templat
cccdna
suitabl
ntcp
complement
cell
cultur
system
high
throughput
screen
approach
facilit
identif
novel
host
factor
involv
hbv
replic
includ
determin
peculiar
host
specif
hbv
infect
enabl
identif
develop
novel
drug
candid
improv
therapeut
sinc
ntcp
major
hostspecif
restrict
factor
hbv
hdv
hntcpexpress
anim
provid
basi
futur
suscept
vivo
model
concept
obtain
entri
inhibitor
myrcludex
b
demonstr
ntcp
suitabl
target
clinic
interfer
viral
entri
foster
clinic
approach
aim
cur
combin
therapi
european
associ
studi
liver
publish
elsevi
bv
right
reserv
natur
cellular
receptor
mediat
hbv
infect
remain
elus
long
time
discoveri
viru
although
candid
molecul
found
bind
envelop
protein
hbv
none
ever
demonstr
viru
receptor
activ
upon
express
nonsuscept
cell
accept
strong
criteria
regard
whether
candid
truli
function
viru
receptor
studi
infect
biolog
hbv
satellit
viru
hepat
viru
hdv
rna
viru
use
hbv
envelop
protein
packag
cellular
entri
hamper
lack
conveni
cell
cultur
system
primari
cultur
human
hepatocyt
phh
primari
tupaia
hepatocyt
pth
hepatoma
cell
line
heparg
differenti
dmso
cell
suscept
hbv
hdv
phh
pth
scarc
suscept
viru
vari
depend
sourc
well
isol
cultur
procedur
heparg
cell
requir
differenti
period
cell
becom
suscept
nonetheless
eleg
work
use
cell
cultur
system
past
decad
reveal
critic
aspect
hbv
entri
infect
hbv
exhibit
extraordinari
speci
organ
specif
indic
exist
highli
specif
interact
viru
hepatocyt
two
hbv
three
envelop
protein
name
small
larg
l
envelop
protein
middl
protein
respons
hbv
entri
antigen
loop
agl
protein
domain
lprotein
essenti
hbv
infect
ntermin
region
domain
requir
uninterrupt
sequenc
amino
acid
genotyp
myristoyl
modif
nterminu
critic
contribut
infect
among
amino
acid
residu
vital
import
correspond
lipopeptid
domain
block
viral
infect
vitro
vivo
lipopeptid
natur
ligand
use
identifi
specif
receptor
hepatocyt
howev
easi
task
find
bind
partner
hepatocyt
sever
nonfunct
molecul
describ
success
discoveri
bona
fide
receptor
sodium
taurochol
cotransport
polypeptid
ntcp
achiev
use
innov
peptid
ligand
combin
proteom
analysi
pth
highli
effici
trace
purif
process
biochem
studi
confirm
interact
liver
specif
bile
acid
transport
remark
transfect
cell
ntcp
express
dna
vector
confer
suscept
otherwis
nonsuscept
cell
find
quickli
confirm
sever
import
studi
includ
studi
demonstr
human
ntcp
confer
suscept
hdv
pseudotyp
envelop
protein
bat
hepadnaviru
woolli
monkey
hbv
wmhbv
also
exploit
ntcp
viral
entri
tupaia
hepatocyt
hbvhdv
exploit
ntcp
speciesspecif
entri
hepatocyt
discoveri
receptor
also
engend
new
perspect
hbv
associ
diseas
ntcp
code
gene
bile
acid
transport
respons
hepat
uptak
major
conjug
bile
acid
blood
play
critic
role
bile
acid
homeostasi
enterohepat
circul
express
ntcp
subcellular
distribut
subject
precis
regul
multipl
level
ntcp
contain
nine
transmembran
segment
embed
cell
membran
structur
remain
elucid
interestingli
although
ntcp
gene
conserv
mammal
disrupt
ntcp
mice
short
term
ca
month
result
signific
abnorm
anim
led
elev
serum
bile
acid
particular
conjug
one
singl
point
mutat
human
ntcp
interfer
surfac
express
hepatocyt
recent
fiveyear
old
girl
bear
mutat
identifi
exhibit
mild
hypotonia
growth
retard
delay
motor
mileston
sever
health
problem
therefor
although
longterm
consequ
disrupt
ntcp
need
studi
physiolog
role
ntcp
probabl
compens
yet
defin
mechan
redund
pathway
may
oper
absenc
ntcp
whether
anoth
receptor
hbv
entri
known
present
howev
sever
line
evid
support
ntcp
well
suit
key
receptor
hbv
fig
predominantli
express
hepatocyt
also
shown
hepatotrop
presligand
vivo
consist
high
liver
specif
hbv
furthermor
ntcp
resid
sinusoid
side
hepatocyt
line
blood
transmiss
viru
low
express
ntcp
hepatocarcinoma
cell
line
like
express
ntcp
rapidli
decreas
isol
primari
hepatocyt
anim
two
featur
least
partial
explain
normal
liver
cancer
cell
resist
hbv
infect
suscept
primari
hepatocyt
persist
day
isol
interestingli
human
popul
studi
hbv
patient
southern
china
guangdong
show
singl
mutat
ntcp
associ
resist
chronic
hepat
b
mutat
found
mainli
asian
popul
minor
frequenc
ca
cell
cultur
mutat
abolish
taurochol
tc
transport
express
ntcp
cell
fail
support
genotyp
hbv
hdv
infect
mark
protect
mutat
hbv
infect
popul
level
strongli
argu
ntcp
major
viral
receptor
human
recent
genet
associ
studi
base
chronic
hepat
b
chb
patient
taiwan
confirm
mutat
confer
resist
hbv
infect
independ
associ
decreas
risk
cirrhosi
hcc
current
unclear
mutat
would
reduc
risk
cirrhosi
hcc
interestingli
five
hbv
patient
homozyg
ntcp
mutat
guangdong
cohort
taiwan
studi
also
found
five
hbv
patient
patient
infect
interest
import
question
sever
possibl
first
cell
surfac
molecul
ntcp
could
mediat
viral
infect
second
viru
adapt
third
patient
genet
mosaic
mean
hepatocyt
might
still
wildtyp
ntcp
clearli
work
need
clarifi
possibl
relat
studi
would
help
deepen
understand
hbv
infect
experiment
anim
howev
hbv
genom
deliv
monkey
hepatocyt
viru
robustli
replic
indic
cell
abl
form
cccdna
replic
viru
mous
hepatocyt
bear
hbv
transgen
produc
infecti
virion
unabl
form
cccdna
observ
support
hypothesi
speci
restrict
hbv
larg
entri
level
entri
restrict
common
crossspeci
transmiss
mani
virus
exampl
infect
influenza
viru
among
mammal
bird
heavili
depend
exist
sialic
acid
sa
saccharid
sa
saccharid
receptor
anim
transmiss
coronavirus
includ
sarscov
merscov
control
receptor
whether
ntcp
respons
speci
specif
entri
level
first
examin
assess
hbv
infect
mediat
ntcp
chimera
crabeat
monkey
macaca
fasciculari
human
small
motif
cover
residu
ntcp
identifi
critic
hbv
infect
highlight
critic
role
ntcp
mediat
hbv
infect
bile
acid
observ
cynomolgu
monkey
hepatocyt
bind
vitro
vivo
strongli
support
find
key
role
residu
hbv
infect
human
also
support
recent
chb
popul
studi
taiwan
mutat
found
region
chb
patient
interestingli
natur
occur
transmiss
hbv
infect
genotyp
report
among
fasciculari
mauritiu
island
howev
viral
titr
low
evid
need
support
hbv
undergo
full
life
cycl
monkey
receptoraddress
bind
primari
hepatocyt
hbv
nonsuscept
anim
mous
rat
dog
find
surpris
indic
resist
anim
hbv
entri
level
less
like
due
lack
specif
bind
partner
viru
hepatocyt
accordingli
either
bind
could
lead
product
infect
differ
isol
peptid
versu
region
resid
virion
extens
map
studi
reveal
amino
acid
residu
first
extracellular
loop
ntcp
restrict
mice
infect
hbv
entri
level
replac
three
four
amino
acid
human
counterpart
effect
render
mous
ntcp
function
receptor
hbv
cell
consist
notion
ntcp
pose
major
barrier
viral
infect
mice
suckl
mice
bear
human
ntcp
suscept
hdv
infect
viru
success
undergo
life
cycl
anim
howev
although
mous
liver
cell
like
supplement
human
ntcp
support
hdv
infect
fail
support
hbv
infect
studi
indic
factor
ntcp
may
also
involv
hbv
infect
although
natur
factor
still
unknown
hbv
infect
studi
base
cell
fusion
assay
mous
cell
indic
infect
mous
cell
limit
lack
host
cell
depend
factor
interestingli
studi
recent
indic
stabil
viral
nucleocapsid
may
determin
cccdna
format
murin
hepatocyt
interestingli
cell
line
supplement
hntcp
support
infect
hbv
import
identifi
cellular
factor
success
establish
small
anim
model
hbv
infect
hand
one
also
awar
viral
infect
tissu
cultur
influenc
variabl
among
differ
cell
clone
dosag
inocul
viru
other
factor
differ
physiolog
condit
therefor
viral
infect
anim
defin
gene
altern
provid
definit
answer
question
ntcp
complement
cell
provid
valuabl
platform
screen
new
host
factor
develop
antivir
hbv
hdv
infect
cell
complement
human
ntcp
provid
easi
access
system
hbvhdv
infect
system
amend
high
throughput
screen
procedur
thu
enabl
studi
system
identif
new
factor
involv
hbvhdv
infect
develop
new
antivir
target
screen
cell
identifi
glypican
entri
factor
hbvhdv
viral
infect
base
assay
found
promis
drug
candid
block
hbvhdv
infect
hbv
undergo
whole
life
cycl
cell
entri
establish
infect
low
effici
releas
progeni
virion
coval
close
circular
dna
cccdna
hbv
reservoir
chronic
infect
wide
believ
major
obstacl
elimin
infect
cell
support
cccdna
format
incom
virion
less
effici
replenish
cccdna
via
intracellular
recycl
interestingli
although
carcinomat
natur
cell
concern
studi
use
cell
recent
studi
indic
epigenet
regul
cccdna
cell
similar
observ
phh
therapeut
interfer
entri
inhibitor
attract
clinic
concept
sinc
inhibit
infect
earliest
step
therebi
prevent
establish
viral
genom
eg
cccdna
regener
host
cell
entri
inhibit
persist
infect
patient
presum
effici
viru
spread
requir
entri
progeni
viru
cell
via
receptormedi
pathway
addit
fast
replenish
infect
cell
cell
would
limit
time
treatment
clear
infect
hiv
shown
direct
spread
one
celltoanoth
occur
might
explain
therapeut
limit
entri
inhibitor
nevertheless
fuzeon
maraviroc
two
approv
entri
inhibitor
show
antivir
activ
patient
hbv
demonstr
spread
phhtransplant
upa
sever
combin
immunodeffici
scid
mice
complet
block
key
point
hntcpexpress
cell
line
allow
high
throughput
approach
drug
identif
ntcpspecif
entri
inhibitor
myrcludex
b
indic
intrahepat
spread
greatli
depend
ntcpmediat
entri
progeni
viru
hepatocyt
moreov
cccdnadissemin
liver
anim
abrog
cell
prolifer
indic
hbv
depend
extracellular
viru
cycl
work
poorli
transfer
cccdna
templat
via
intercellular
pathway
progeni
cell
thu
entri
inhibit
hbv
may
becom
clinic
import
order
block
cccdna
reform
either
natur
immunemediatedinduc
hepatocyt
turnov
entri
inhibit
achiev
target
viral
structur
eg
neutralis
envelop
protein
viral
surfac
involv
receptor
bind
cours
resolut
acut
infect
neutralis
antibodi
fulfil
crucial
role
therefor
indispens
clear
viru
accordingli
antibodi
recogn
envelop
protein
develop
therapeut
purpos
current
neutralis
antibodi
preferenti
appli
prophylact
clinic
set
hbv
hdv
antibodi
prevent
reinfect
liver
transplant
infect
patient
effect
post
exposur
prophylaxi
prevent
motherchild
transmiss
longterm
administr
hbv
neutralis
antibodi
chronic
infect
patient
perform
far
altern
strategi
inhibit
viral
entri
take
advantag
drug
target
cellular
receptorscoreceptor
approach
rel
new
shown
work
hiv
infect
patient
mode
action
base
sustain
inhibit
de
novo
format
viral
templat
although
cur
hiv
infect
patient
theoret
bear
potenti
even
without
involv
adapt
immun
respons
recent
demonstr
immunedefici
anim
model
hepat
c
viru
hcv
infect
howev
durat
treatment
gain
viru
elimin
depend
natur
turnov
rate
infect
cell
halflif
time
viru
presenc
possibl
viral
reservoir
establish
host
importantli
immun
respons
direct
infect
cell
may
dramat
enhanc
clearanc
infect
cell
accordingli
entri
inhibit
may
highli
synergist
combin
immun
therapeut
approach
whether
viru
receptor
suitabl
drugabl
target
depend
differ
aspect
firstli
viru
spread
within
organ
subject
receptormedi
de
novo
infect
primarili
proceed
celltocel
transmiss
viral
genom
secondli
sinc
viru
receptor
often
serv
import
cellular
function
drug
complet
mess
natur
function
molecul
clinic
manag
achiev
target
drug
block
receptor
function
ic
concentr
requir
inactiv
cellular
function
therapeut
window
would
allow
drug
dose
clinic
accept
even
target
molecul
display
essenti
function
altern
receptor
may
essenti
protein
function
might
compens
salvag
pathway
final
interact
drug
receptor
highli
specif
order
avoid
offtarget
effect
hbv
specif
target
hepatocyt
human
liver
high
efficaci
hepatotrop
relat
specif
interact
viral
envelop
protein
host
factor
includ
heparan
sulfat
proteoglycan
hspg
ntcp
see
shown
known
substrat
ntcp
well
hspg
interfer
hbv
hdv
infect
substanc
subdivid
differ
group
firstli
natur
artifici
substrat
hspg
like
heparin
highli
sulphat
dextran
suramin
neg
charg
polym
shall
discuss
secondli
substrat
ntcp
like
conjug
bile
acid
tc
glycochol
acid
substrat
also
bile
salt
homologu
transport
ntcp
sodium
depend
manner
bind
pocket
outward
conform
ntcp
releas
togeth
two
sodium
ion
substanti
structur
chang
inward
conform
cytoplasm
hepatocyt
high
concentr
conjug
bile
salt
inhibit
hbv
hdv
infect
concentr
need
infect
inhibit
normal
bile
salt
level
healthi
hbv
infect
individu
probabl
explain
lack
therapeut
effect
bile
salt
hbvhdv
infect
patient
addit
endogen
substrat
xenobiot
certain
drug
shown
use
transport
function
ntcp
enter
hepatocyt
molecul
develop
drug
discov
ntcp
address
agent
cours
pharmacokinet
characterist
one
exampl
ezetimib
use
inhibitor
primari
cholesterol
transport
intestin
lumen
also
substrat
ntcp
later
shown
interfer
hbv
hdv
entri
substanc
common
mechan
hbv
receptor
inhibit
coupl
abil
bind
substrat
bile
salt
pocket
therebi
block
receptor
interact
viru
evid
come
find
determin
viral
entri
bile
salt
transport
function
overlap
accordingli
report
k
transport
activ
hbv
inhibit
activ
compar
futur
interest
see
whether
small
molecul
bind
ntcp
substrat
pocket
eg
bile
salt
analogu
might
coval
bind
transport
could
act
irrevers
deadend
inhibitor
third
class
ntcp
inhibitor
peptid
substrat
bind
presum
transport
ntcp
prototyp
member
famili
cyclosporin
known
ntcpinhibitor
describ
hbv
receptor
antivir
activ
restrict
natur
product
cyclosporin
also
hold
deriv
includ
nonimmunosupress
variant
like
alisporivir
like
myrcludex
b
see
ic
cyclosporin
inhibit
hbv
hdv
infect
significantli
lower
compar
inhibitori
effect
taurochol
tc
uptak
indic
therapeut
effect
hbv
might
achiev
nonntcpsatur
concentr
howev
sinc
cyclosporin
specif
ntcp
inhibit
addit
modul
intracellular
cyclophilin
bile
salt
transport
like
organ
aniontransport
polypeptid
oatp
even
lower
concentr
therapeut
use
chb
chronic
hdv
infect
might
limit
hbv
lprotein
deriv
lipopeptid
highli
specif
inhibitor
ntcp
due
high
sequenc
homolog
receptor
bind
site
ntermin
primat
hbv
like
wmhbv
gorilla
hbv
even
recent
discov
bathepat
b
virus
assum
specif
bind
respect
host
ntcp
interact
occur
preced
interact
possibl
activ
hspg
remark
virion
expos
ntermin
ntcp
bind
site
surfac
accordingli
hbv
may
hardli
recogn
inhibit
monoclon
antibodi
recogn
motif
moreov
chronic
infect
patient
high
load
prescontain
virion
subvir
particl
show
elev
serum
bile
salt
level
indic
ntcp
may
partial
block
presenc
particl
contrast
synthet
lipopeptid
contain
nplgffpmotif
potent
ntcpbinder
block
bile
salt
transport
function
peptid
character
extens
regard
specif
activ
role
fatti
acid
moieti
requir
anchor
peptid
membran
close
ntcp
bind
site
lead
substanc
peptid
present
clinic
develop
myrcludex
b
effici
inhibit
hbv
hdv
infect
hepatocyt
alreadi
picomolar
concentr
notabl
myrcludex
b
peptid
drug
amino
acid
contain
presspecif
epitop
includ
essenti
receptor
bind
motif
also
contain
ctermin
locat
epitop
eg
may
induc
highli
neutralis
antibodi
accordingli
myrcludex
b
therapi
may
induc
antipresspecif
antibodi
might
help
elimin
hbv
hdv
liver
contrast
small
substrat
molecul
mention
presderiv
lipopeptid
includ
myrcludex
b
clinic
use
lead
substanc
alloster
inhibitor
ntcp
irrevers
bind
inactiv
hbv
receptor
function
molecul
peptid
also
inhibit
bile
acid
transport
function
ca
higher
concentr
function
recoveri
ntcp
slow
probabl
possibl
presreceptor
complex
dissoci
endocyt
turnov
replac
de
novo
synthesi
whether
function
recycl
ntcp
format
prescomplex
occur
present
unknown
reason
remark
differ
ic
eg
myrcludex
b
bile
salt
transport
ic
ca
nm
activ
hbvhdv
infect
inhibit
ca
nm
still
unclear
howev
plausibl
assumpt
hbv
lprotein
form
multimer
eg
trimer
complex
ntcp
shown
mani
envelop
virus
complex
could
function
inactiv
one
three
bind
site
occupi
peptid
fragment
fact
ntcp
shown
form
multimer
complex
therapeut
point
view
allow
inactiv
receptor
function
ntcp
dose
significantli
affect
natur
function
bile
salt
transport
phase
safeti
trial
reveal
myrcludex
b
first
class
entri
inhibitor
address
ntcpreceptor
hbv
well
toler
healthi
volunt
intraven
appli
dose
mg
pharmacokinet
studi
reveal
dose
mg
subcutan
result
ntcp
satur
least
h
blank
trial
perform
hbeagneg
hbv
monoinfect
patient
show
reduct
hbv
serum
level
mean
within
week
treatment
mg
arm
assum
myrcludex
b
interfer
de
novo
infect
cell
rate
viru
product
per
infect
cell
remain
unchang
indic
substanti
reduct
number
infect
cell
treatment
howev
proven
directli
futur
studi
immunohistochemistri
liver
biopsi
sub
studi
hdv
coinfect
hbv
patient
bogolomov
et
al
revis
myrcludex
b
appli
either
alon
mg
daili
combin
pegifn
week
myrcludex
b
well
toler
patient
slightli
increas
conjug
bile
salt
level
within
week
hdv
rna
declin
log
cohort
even
becam
neg
two
patient
myrcludex
b
pegifn
control
arm
remark
negativ
observ
five
seven
evalu
patient
myrcludex
b
pegifn
combin
arm
indic
synergist
effect
drug
taken
togeth
first
proof
concept
studi
use
myrcludex
b
demonstr
target
ntcp
key
molecul
hepatocyt
specif
entri
hbv
feasibl
clinic
concept
futur
therapeut
approach
aim
function
cure
chronic
hepat
b
hepat
interest
see
longterm
inhibit
viral
entri
result
hbsag
loss
antihbsag
seroconvers
whether
combin
immunomodulatori
drug
like
ifnalpha
induc
andor
acceler
process
